{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T07:05:36Z","timestamp":1766732736496,"version":"3.40.5"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T00:00:00Z","timestamp":1707350400000},"content-version":"vor","delay-in-days":38,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Therapeutic Research"],"published-print":{"date-parts":[[2024]]},"DOI":"10.1016\/j.curtheres.2024.100738","type":"journal-article","created":{"date-parts":[[2024,2,18]],"date-time":"2024-02-18T06:22:17Z","timestamp":1708237337000},"page":"100738","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Usefulness of Belimumab in Adult Patients With Systemic Lupus Erythematosus Evaluated Using Single Indexes: A Meta-Analysis and Systematic Review"],"prefix":"10.1016","volume":"100","author":[{"given":"Chisato","family":"Yoshijima","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7092-4618","authenticated-orcid":false,"given":"Yosuke","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayako","family":"Oda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryota","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Ono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiko","family":"Ohno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.curtheres.2024.100738_bib0001","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1136\/annrheumdis-2020-218272","article-title":"Update on the diagnosis and management of systemic lupus erythematosus","volume":"80","author":"Fanouriakis","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.curtheres.2024.100738_bib0002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2018.11.001","article-title":"Systemic lupus erythematosus: diagnosis and clinical management","volume":"96","author":"Fava","year":"2019","journal-title":"J Autoimmun"},{"issue":"6","key":"10.1016\/j.curtheres.2024.100738_bib0003","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","article-title":"2019 update of the EULAR recommendations for the management of systemic lupus erythematosus","volume":"78","author":"Fanouriakis","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.curtheres.2024.100738_bib0004","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1136\/ard.2007.070367","article-title":"EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics","volume":"67","author":"Bertsias","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.curtheres.2024.100738_bib0005","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s40265-018-0872-z","article-title":"Belimumab: a review in systemic lupus erythematosus","volume":"78","author":"Blair","year":"2018","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.curtheres.2024.100738_bib0006","first-page":"464","article-title":"Belimumab human genome sciences\/Cambridge Antibody Technology\/GlaxoSmithKline","volume":"7","author":"Ding","year":"2006","journal-title":"Curr Opin Investig Drugs"},{"issue":"1","key":"10.1016\/j.curtheres.2024.100738_bib0007","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s13075-015-0702-6","article-title":"Measuring disease activity in adults with systemic lupus erythematosus: the challenges of administrative burden and responsiveness to patient concerns in clinical research","volume":"17","author":"Mikdashi","year":"2015","journal-title":"Arthritis Res Ther"},{"issue":"9","key":"10.1016\/j.curtheres.2024.100738_bib0008","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1002\/art.24698","article-title":"Novel evidence-based systemic lupus erythematosus responder index","volume":"61","author":"Furie","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"41","key":"10.1016\/j.curtheres.2024.100738_bib0009","doi-asserted-by":"crossref","first-page":"6306","DOI":"10.2174\/1381612822666160831103254","article-title":"A review of clinical trials of belimumab in the management of systemic lupus erythematosus","volume":"22","author":"Garcia","year":"2016","journal-title":"Curr Pharm Des"},{"issue":"1","key":"10.1016\/j.curtheres.2024.100738_bib0010","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/rheumatology\/kex286","article-title":"The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults","volume":"57","author":"Gordon","year":"2018","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.curtheres.2024.100738_bib0011","first-page":"172","article-title":"2020 Chinese guidelines for the diagnosis and treatment of systemic lupus erythematosus","volume":"59","year":"2020","journal-title":"Chin J Intern Med"},{"issue":"12","key":"10.1016\/j.curtheres.2024.100738_bib0012","doi-asserted-by":"crossref","first-page":"3622","DOI":"10.1093\/rheumatology\/keaa383","article-title":"Use of Physician Global Assessment in systemic lupus erythematosus: a systematic review of its psychometric properties","volume":"59","author":"Chessa","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.curtheres.2024.100738_bib0013","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/art.1780350606","article-title":"Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE","volume":"35","author":"Bombardier","year":"1992","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.curtheres.2024.100738_bib0014","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1093\/rheumatology\/keh624","article-title":"Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus","volume":"44","author":"Isenberg","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.curtheres.2024.100738_bib0015","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1146\/annurev.psych.52.1.59","article-title":"Meta-analysis: recent developments in quantitative methods for literature reviews","volume":"52","author":"Rosenthal","year":"2001","journal-title":"Annu Rev Psychol"},{"issue":"2","key":"10.1016\/j.curtheres.2024.100738_bib0016","article-title":"Belimumab for systemic lupus erythematosus","volume":"2","author":"Singh","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"10.1016\/j.curtheres.2024.100738_bib0017","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.clinthera.2016.02.022","article-title":"Efficacy and safety of belimumab plus standard therapy in patients with systemic lupus erythematosus: a meta-analysis","volume":"38","author":"Wei","year":"2016","journal-title":"Clin Ther"},{"issue":"1","key":"10.1016\/j.curtheres.2024.100738_bib0018","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13643-021-01626-4","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"10","author":"Page","year":"2021","journal-title":"Syst Rev"},{"issue":"1","key":"10.1016\/j.curtheres.2024.100738_bib0019","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.curtheres.2024.100738_bib0020","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.curtheres.2024.100738_bib0021","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments","volume":"12","author":"McGuinness","year":"2021","journal-title":"Res Synth Methods"},{"issue":"12","key":"10.1016\/j.curtheres.2024.100738_bib0022","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1002\/art.30613","article-title":"A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus","volume":"63","author":"Furie","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.curtheres.2024.100738_bib0023","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/art.41900","article-title":"Phase III\/IV, randomized, fifty-two-week study of the efficacy and safety of belimumab in patients of black African ancestry with systemic lupus erythematosus","volume":"74","author":"Ginzler","year":"2022","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.curtheres.2024.100738_bib0024","doi-asserted-by":"crossref","first-page":"300","DOI":"10.3899\/jrheum.121368","article-title":"Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus","volume":"41","author":"Ginzler","year":"2014","journal-title":"J. Rheumatol."},{"issue":"10","key":"10.1016\/j.curtheres.2024.100738_bib0025","doi-asserted-by":"crossref","first-page":"3364","DOI":"10.1002\/art.34564","article-title":"Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus","volume":"64","author":"Merrill","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"9767","key":"10.1016\/j.curtheres.2024.100738_bib0026","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.curtheres.2024.100738_bib0027","doi-asserted-by":"crossref","first-page":"e122","DOI":"10.1016\/S2665-9913(20)30355-6","article-title":"Mortality and adverse events of special interest with intravenous belimumab for adults with active, autoantibody-positive systemic lupus erythematosus (BASE): a multicentre, double-blind, randomised, placebo-controlled, phase 4 trial","volume":"3","author":"Sheikh","year":"2021","journal-title":"Lancet Rheumatol"},{"issue":"12","key":"10.1016\/j.curtheres.2024.100738_bib0028","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.7326\/M21-2078","article-title":"Effectiveness of belimumab after rituximab in systemic lupus erythematosus : a randomized controlled trial","volume":"174","author":"Shipa","year":"2021","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.curtheres.2024.100738_bib0029","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1002\/art.40049","article-title":"Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: a fifty-two-week randomized, double-blind, placebo-controlled study","volume":"69","author":"Stohl","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.curtheres.2024.100738_bib0030","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1080\/14397595.2019.1630897","article-title":"Organ system improvements in Japanese patients with systemic lupus erythematosus treated with belimumab: a subgroup analysis from a phase 3 randomized placebo-controlled trial","volume":"30","author":"Tanaka","year":"2020","journal-title":"Mod Rheumatol"},{"issue":"3","key":"10.1016\/j.curtheres.2024.100738_bib0031","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1080\/14397595.2018.1480915","article-title":"Efficacy and safety of intravenous belimumab in Japanese patients with systemic lupus erythematosus: a subgroup analysis of a phase 3 randomized placebo-controlled trial","volume":"29","author":"Tanaka","year":"2019","journal-title":"Mod Rheumatol"},{"issue":"9","key":"10.1016\/j.curtheres.2024.100738_bib0032","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1002\/art.24699","article-title":"A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus","volume":"61","author":"Wallace","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.curtheres.2024.100738_bib0033","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1136\/annrheumdis-2017-211631","article-title":"A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea","volume":"77","author":"Zhang","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.curtheres.2024.100738_bib0034","first-page":"288","article-title":"Systemic lupus erythematosus disease activity index 2000","volume":"29","author":"Gladman","year":"2002","journal-title":"J Rheumatol"},{"issue":"24","key":"10.1016\/j.curtheres.2024.100738_bib0035","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1056\/NEJMoa051135","article-title":"Combined oral contraceptives in women with systemic lupus erythematosus","volume":"353","author":"Petri","year":"2005","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.curtheres.2024.100738_bib0036","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1080\/14397595.2020.1775928","article-title":"Which is the best SLE activity index for clinical trials?","volume":"31","author":"Ohmura","year":"2021","journal-title":"Mod Rheumatol"},{"issue":"10","key":"10.1016\/j.curtheres.2024.100738_bib0037","doi-asserted-by":"crossref","first-page":"765","DOI":"10.2217\/cer-2022-0040","article-title":"Indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus","volume":"11","author":"Bruce","year":"2022","journal-title":"J Comp Eff Res"},{"issue":"6","key":"10.1016\/j.curtheres.2024.100738_bib0038","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/acr.20133","article-title":"Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus","volume":"62","author":"Wolfe","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"9","key":"10.1016\/j.curtheres.2024.100738_bib0039","first-page":"1955","article-title":"Accrual of organ damage over time in patients with systemic lupus erythematosus","volume":"30","author":"Gladman","year":"2003","journal-title":"J Rheumatol"},{"issue":"8","key":"10.1016\/j.curtheres.2024.100738_bib0040","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1002\/1529-0131(200008)43:8<1801::AID-ANR16>3.0.CO;2-O","article-title":"Damage in systemic lupus erythematosus and its association with corticosteroids","volume":"43","author":"Zonana-Nacach","year":"2000","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.curtheres.2024.100738_bib0041","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2015-000118","article-title":"Response to belimumab among patients with systemic lupus erythematosus in clinical practice settings: 24-month results from the OBSErve study in the USA","volume":"3","author":"Collins","year":"2016","journal-title":"Lupus Sci Med"},{"issue":"6","key":"10.1016\/j.curtheres.2024.100738_bib0042","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s00296-017-3682-9","article-title":"Belimumab use, clinical outcomes and glucocorticoid reduction in patients with systemic lupus erythematosus receiving belimumab in clinical practice settings: results from the OBSErve Canada Study","volume":"37","author":"Touma","year":"2017","journal-title":"Rheumatol Int"}],"container-title":["Current Therapeutic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011393X24000080?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011393X24000080?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T10:28:50Z","timestamp":1730975330000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0011393X24000080"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":42,"alternative-id":["S0011393X24000080"],"URL":"https:\/\/doi.org\/10.1016\/j.curtheres.2024.100738","relation":{},"ISSN":["0011-393X"],"issn-type":[{"type":"print","value":"0011-393X"}],"subject":[],"published":{"date-parts":[[2024]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Usefulness of Belimumab in Adult Patients With Systemic Lupus Erythematosus Evaluated Using Single Indexes: A Meta-Analysis and Systematic Review","name":"articletitle","label":"Article Title"},{"value":"Current Therapeutic Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.curtheres.2024.100738","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100738"}}